The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | Mechanism of action of belantamab mafodotin
James Berenson, MD, Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, outlines the mechanism of action of belantamab mafodotin, an anti-B cell maturation antigen (BCMA) antibody-drug conjugate indicated for relapsed/refractory multiple myeloma. Belantamab selectively binds to BCMA and the conjugated monomethyl auristatin F (MMAF) mediates myeloma cell death. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
Disclosures
Speaker’s Bureau, Consulting, and Research Grant Support: BMS, Takeda Oncology, Karyopharm, Oncopeptides, and AMGEN
Speaker’s Bureau: Janssen and AMAG
Major Stockholder: ONCOtracker
